ImmunoGen treatment receives orphan-drug status in U.S., Europe

03/8/2010 | Google

ImmunoGen's cancer drug candidate IMGN901 received orphan-drug designation from U.S. and European regulators. The company is seeking to market the treatment for Merkel cell carcinoma, a form of skin cancer.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN